Taysha Gene Therapies, Inc. Earnings Per Share (Basic)
Taysha Gene Therapies, Inc. (TSHA) reported Earnings Per Share (Basic) of -$0.13 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-11
- Taysha Gene Therapies, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.13.
- Taysha Gene Therapies, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.12.
- Taysha Gene Therapies, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.08.
- Taysha Gene Therapies, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.09.
- Taysha Gene Therapies, Inc. earnings per share, basic for fiscal 2025 was -$0.34.
- Taysha Gene Therapies, Inc. earnings per share, basic for fiscal 2024 was -$0.36.
- Taysha Gene Therapies, Inc. earnings per share, basic for fiscal 2023 was -$0.96.
- Taysha Gene Therapies, Inc. earnings per share, basic for fiscal 2022 was -$3.78.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.13 10-Q · filed 2026-08-11 | -$0.24 10-Q · filed 2026-08-11 | -$0.32 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.41 derived: net income ÷ weighted average shares · filed 2026-08-11 | |||
| 2026-03-31 | -$0.12 10-Q · filed 2026-05-06 | -$0.19 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$0.29 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$0.38 derived: net income ÷ weighted average shares · filed 2026-08-11 | |||
| 2025-12-31 | -$0.08 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$0.17 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$0.26 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.34 10-K · filed 2026-03-19 | |||
| 2025-09-30 | -$0.09 10-Q · filed 2025-11-04 | -$0.18 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.26 10-Q · filed 2025-11-04 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-08-11 | |||
| 2025-06-30 | -$0.09 10-Q · filed 2026-08-11 | -$0.17 10-Q · filed 2026-08-11 | -$0.24 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-08-11 | |||
| 2025-03-31 | -$0.08 10-Q · filed 2026-05-06 | -$0.15 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$0.25 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$0.33 derived: net income ÷ weighted average shares · filed 2026-05-06 | |||
| 2024-12-31 | -$0.07 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$0.17 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$0.25 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$0.36 10-K · filed 2026-03-19 | |||
| 2024-09-30 | -$0.10 10-Q · filed 2025-11-04 | -$0.19 derived: net income ÷ weighted average shares · filed 2025-11-04 | -$0.29 10-Q · filed 2025-11-04 | -$0.10 derived: net income ÷ weighted average shares · filed 2025-11-04 | |||
| 2024-06-30 | -$0.09 10-Q · filed 2025-08-12 | -$0.19 10-Q · filed 2025-08-12 | $0.01 derived: net income ÷ weighted average shares · filed 2025-08-12 | -$0.57 derived: net income ÷ weighted average shares · filed 2025-08-12 | |||
| 2024-03-31 | -$0.10 10-Q · filed 2025-05-15 | $0.11 derived: net income ÷ weighted average shares · filed 2025-05-15 | -$0.49 derived: net income ÷ weighted average shares · filed 2025-05-15 | -$0.75 derived: net income ÷ weighted average shares · filed 2025-05-15 | |||
| 2023-12-31 | $0.23 derived: net income ÷ weighted average shares · filed 2025-02-26 | -$0.41 derived: net income ÷ weighted average shares · filed 2025-02-26 | -$0.70 derived: net income ÷ weighted average shares · filed 2025-02-26 | -$0.96 10-K · filed 2025-02-26 | |||
| 2023-09-30 | -$0.93 10-Q · filed 2024-11-13 | -$1.49 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$1.88 10-Q · filed 2024-11-13 | -$2.77 derived: net income ÷ weighted average shares · filed 2024-11-13 | |||
| 2023-06-30 | -$0.38 10-Q · filed 2024-08-12 | -$0.66 10-Q · filed 2024-08-12 | -$1.59 derived: net income ÷ weighted average shares · filed 2024-08-12 | -$2.20 derived: net income ÷ weighted average shares · filed 2024-08-12 | |||
| 2023-03-31 | -$0.28 10-Q · filed 2024-05-14 | -$1.21 derived: net income ÷ weighted average shares · filed 2024-05-14 | -$1.85 derived: net income ÷ weighted average shares · filed 2024-05-14 | -$2.65 derived: net income ÷ weighted average shares · filed 2024-05-14 | |||
| 2022-12-31 | -$0.97 derived: net income ÷ weighted average shares · filed 2024-03-19 | -$1.67 derived: net income ÷ weighted average shares · filed 2024-03-19 | -$2.52 derived: net income ÷ weighted average shares · filed 2024-03-19 | -$3.78 10-K · filed 2024-03-19 | |||
| 2022-09-30 | -$0.65 10-Q · filed 2023-11-14 | -$0.64 10-Q · filed 2022-11-08 | -$1.50 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$2.79 10-Q · filed 2023-11-14 | -$2.77 10-Q · filed 2022-11-08 | -$4.10 derived: net income ÷ weighted average shares · filed 2023-11-14 | |
| 2022-06-30 | -$0.85 10-Q · filed 2023-08-14 | -$0.84 10-Q · filed 2022-08-11 | -$2.16 10-Q · filed 2023-08-14 | -$2.14 10-Q · filed 2022-08-11 | -$3.47 derived: net income ÷ weighted average shares · filed 2023-08-14 | -$4.82 derived: net income ÷ weighted average shares · filed 2023-08-14 | |
| 2022-03-31 | -$1.32 10-Q · filed 2023-05-11 | -$2.64 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$3.99 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$5.08 derived: net income ÷ weighted average shares · filed 2023-05-11 | |||
| 2021-12-31 | -$1.32 derived: net income ÷ weighted average shares · filed 2023-03-28 | -$2.67 derived: net income ÷ weighted average shares · filed 2023-03-28 | -$3.76 derived: net income ÷ weighted average shares · filed 2023-03-28 | -$4.64 10-K · filed 2023-03-28 | |||
| 2021-09-30 | -$1.35 10-Q · filed 2022-11-08 | -$2.44 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$3.31 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | -$1.09 10-Q · filed 2022-08-11 | -$1.96 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |